Ophthalmology

Persistent DME more likely with bevacizumab treatment

(HealthDay)—For patients with diabetic macular edema (DME), persistence is more likely with bevacizumab than with aflibercept or ranibizumab, according to a study published online Feb. 1 in JAMA Ophthalmology.

Oncology & Cancer

Bevacizumab safe, stable for multiple dosing from single vial

(HealthDay)—Bevacizumab is safe and stable when stored at 4 degrees Celsius, even with multiple dosing from a single vial, according to a study published in the July issue of Clinical & Experimental Ophthalmology.

Oncology & Cancer

Atezolizumab + bevacizumab shows benefit in met renal CA

(HealthDay)—For patients with metastatic renal cell carcinoma (mRCC), atezolizumab plus bevacizumab is associated with a progression-free survival benefit versus sunitinib, according to a study presented at the American ...

Ophthalmology

Bevacizumab, triamcinolone up outcome after cataract surgery

(HealthDay)—For patients undergoing cataract surgery, both bevacizumab and triamcinolone administered at the time of surgery correlate with improvements in visual acuity (VA), but only triamcinolone is associated with sustained ...

Oncology & Cancer

Biomarker predicts response to cancer treatment

VIB researcher Diether Lambrechts, associated with KU Leuven, has discovered a biomarker that might potentially predict which patients will benefit more from treatment with bevacizumab (Avastin). If validated, this discovery ...

page 7 from 12